The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Results of symptomatic improvement in the Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ)
Timeframe: Baseline (prior to study treatment) to 56 weeks post treatment
Results of symptomatic improvement in the Michigan Hand Outcomes Questionnaire (MHQ)
Timeframe: Baseline (prior to study treatment) to 56 weeks post treatment.